ScreenerHero

SEPN Septerna, Inc.

NAS · US · Healthcare · Biotechnology · septerna.com
35.44USD-1.57%Mkt Cap: 1.68B $P/E: —

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?

Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Conference on September 10. At a last close of US$38.51, Septerna’s recent moves tell a mixed story, with the share price return up 2.01% over 1 day and 4.79% over 7 days, yet down 13.46% over 30 days. The year to date share price return of 37.63% and 1 year total shareholder...

Simply Wall St.
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks